You Position: Home > Paper
来氟米特治疗免疫性皮肤病的应用进展
( views:170, downloads:12 )
- Author:
- No author available
- Issue:
- 2
- DOI:
- 10.3760/cma.j.issn.1673-4173.2003.02.003
- Key Word:
- 来氟米特;皮肤疾病
Abstract： 来氟米特是一种用于治疗多种免疫性疾病的药物,具有独特的作用机制,国内外多用于类风湿关节炎的治疗.近年来该药已开始应用于免疫性皮肤病的治疗,其中包括银屑病、结缔组织疾病(红斑狼疮、Sjogren综合征)等.为此,文中对来氟米特的理化性质、药代动力学、药理机制及其在免疫性皮肤病中的应用综述如下.
- [1]T S, Blackwell,J W, Christman.The role of nuclear factor-kappa B in cytokine gene regulation.[J].1997,17(1).
- [2]K. Reich,K.M. Hummel,I. Beckmann,etc.Treatment of severe psoriasis and psoriatic arthritis with leflunomide[J].2002,146(2).
- [3]Herrmann ML,Schleyerbach R,Kirschbaum BJ.Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.[J].2000,47(2).
- [4]D, Thanos,T, Maniatis.NF-kappa B: a lesson in family values.[J].1995,80(4).
- [5]D E, Furst.Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors.[J].1999,38 Suppl 2.
- [6]G, Haberhauer,E M, Kittl,A, Dunky,etc.Beneficial effects of leflunomide in glucocorticoid- and methotrexate-resistant Takayasu's arteritis.[J].1900,19.
- [7]Fox, R.I..Sjögren’s syndrome: current therapies remain inadequate for a common disease[J].2000,9(9).
- [8]Aggarwal BB,Manna SK.Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.[J].1999,162(4).
- [9]E. R. JARMAN,A. KUBA,E. MONTERMANN,etc.Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide[J].1999,115(2).
- [10]Mirmohammadsadegh A,Homey B,Abts HF,etc.Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.[J].1998,55(9).
- [11]M J, Kaplan.Leflunomide Aventis Pharma.[J].2001,2(2).
- [12]H C, Nousari,G J, Anhalt.Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent.[J].2000,136(10).
- [13]Affolter,VK,Moore,PF.Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells.[J].2000,22(1).
- [14]H M, Cherwinski,N, Byars,S J, Ballaron,etc.Leflunomide interferes with pyrimidine nucleotide biosynthesis.[J].1995,44(8).
- [15]Gong H,Jack HM,Williams JW,etc.Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.[J].1998,160(4).
- [16]Suzanne Sanders,Valee Harisdangkul.Leflunomide for the Treatment of Rheumatoid Arthritis and Autoimmunity[J].2002,323(4).
- [17]Wahl GM,Strand V,Fox RI,etc.Mechanism of action for leflunomide in rheumatoid arthritis.[J].1999,93(3).
- [18]Zhu YI,Stiller MJ.Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology.[J].2000,13(5).
- [19]D, Wallace.Current and emerging lupus treatments.[J].2001,7(16 Suppl).